Search the Newsreel

Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). …

Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00

Stifel Nicolaus has reduced its price target for RxSight (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a "hold" rating, suggesting an 11.82% potential upside. Despite the lowered target, RxSight recently reported better-than-expected quarterly results, surpassing analyst estimates for both earnings per share and revenue. …

Stifel cuts RxSight stock price target on competitive headwinds

Stifel lowered its price target for RxSight Inc. (NASDAQ:RXST) to $7.00 from $8.00 due to competitive headwinds, while maintaining a Hold rating. Despite the stock appearing undervalued and recent Q2 2026 earnings beating expectations, the company withdrew its full-year guidance. Stifel anticipates a turnaround …

RxSight (RXST) offers to swap 4.08M underwater options for new awards

RxSight, Inc. has initiated an employee stock option exchange offer for up to 4,083,693 underwater options issued under its 2021 Equity Incentive Plan. Eligible U.S.-based employees can exchange options with exercise prices at or above $6.00 (or $10.00 for named executive officers) for new …

RxSight Reports Q2 Financial Results, Provides Update on 2026 Outlook

RxSight, Inc. announced its financial results for Q2 2026, reporting $33.7 million in total revenue, including $6.5 million from a collaboration with Alcon. Product sales decreased by 19 percent due to competitive pressures. The company also announced a leadership transition and withdrew its 2026 …

Wall Street Zen Upgrades RxSight (NASDAQ:RXST) to Hold

Wall Street Zen has upgraded RxSight (NASDAQ:RXST) from a "sell" to a "hold" rating, while the broader analyst consensus remains "Reduce" with an $8.59 average price target. This upgrade follows RxSight reporting better-than-expected quarterly results, with a loss of $0.29 per share against an …

Levi & Korsinsky Notifies RxSight, Inc. (RXST) Investors - Lead Plaintiff Deadline on September 22, 2025

Levi & Korsinsky LLP has announced a lead plaintiff deadline of September 22, 2025, for investors of RxSight, Inc. (RXST) who suffered losses. The class action securities lawsuit alleges that RxSight made false statements regarding "adoption challenges," overstated product demand, and was unlikely to …

Rxsight Inc (RXST) Stock News Today

RxSight, Inc. Stock 12‑Month Price Target Cut to $7.91, Implies 26% Upside

RxSight, Inc.'s average stock price target has been reduced from $8.06 to $7.91 by 8 analysts, with individual forecasts ranging from $6 to $11 per share. This new target suggests a potential upside of approximately 26% based on the recent closing price. The consensus …

RxSight (RXST) Stock Faces Margin Strain After Guidance Withdrawal

RXST|Rxsight Inc|Price:6.260|Chg%:+0.180

Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside

RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite …

RxSight Q2 Earnings Call Highlights

RxSight reported Q2 revenue of $33.7 million, with product sales down 19% year-over-year excluding collaboration revenue, due to competitive trialing and market headwinds. The new CEO, Aziz Mottiwala, has withdrawn full-year financial guidance to conduct a comprehensive assessment of the business and commercial strategy, …

New RxSight lenses are intended to reduce post-surgery office visits

RxSight, Inc. (NASDAQ: RXST) reported Q2 2026 revenue of $33.7 million, flat year-over-year, and a net loss of $12.1 million. The company announced a strategic collaboration with Alcon, appointed a new CEO, and introduced a next-generation Light Adjustable Technology platform with new lenses designed …

RxSight Q2 FY26 net loss widens 2.6% to $12.1 million; revenue rises 0.3% to $33.7 million

RxSight reported a Q2 FY26 net loss of $12.1 million, a 2.6% increase, despite a 0.3% rise in revenue to $33.7 million. The revenue increase was primarily driven by a $6.5 million license fee, which offset a 19% decline in product sales. The company's …

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) reported a narrower-than-expected Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.21 loss, and surpassed revenue estimates with $33.74 million. Despite beating estimates, the company's shares have fallen 40% year-to-date, while the broader S&P 500 gained …

Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance

RxSight reported better-than-expected Q2 2026 earnings and revenue, but its stock fell after the company withdrew its full-year guidance due to ongoing pressure in its core business. The ophthalmology company's adjusted EPS beat estimates by $0.25, and revenue topped forecasts, partly aided by a …

RxSight (RXST) Stock Falls on Q2 2026 Earnings

RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite …

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RxSight, Inc. reported its financial results for the second quarter of 2026, with total revenue reaching $33.7 million, including $6.5 million from its collaboration with Alcon. The company also announced key strategic developments, such as the appointment of Aziz Mottiwala as CEO and a …

RxSight, Inc. (RXST) Tops Q2 EPS by 25c

RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2, with earnings per share of ($0.11), significantly surpassing analyst estimates of ($0.36) by $0.25. The company's revenue also exceeded expectations, coming in at $33.74 million against a consensus estimate of $32.21 million.

RxSight (NASDAQ: RXST) reports $33.7M Q2 revenue and $60M Alcon collaboration

Rxsight earnings beat by $0.25, revenue topped estimates

RxSight (NASDAQ:RXST) Releases Earnings Results, Beats Estimates By $0.22 EPS

RxSight (RXST): Millennium entities, Israel Englander report 7.3% ownership stake

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 7.3% ownership stake in RxSight, Inc. (RXST), totaling 3,030,287 shares as of June 30, 2026. The filing indicates that all beneficially owned shares have shared voting and dispositive power, with …

Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities. The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. Investors who purchased RxSight securities before November 7, 2024, and continue to hold …

RxSight, Inc. expected to post a loss of 33 cents a share - Earnings Preview

RxSight, Inc. is projected to report an earnings loss of 33 cents per share. This information comes from a Refinitiv earnings preview. The full article is available on TradingView, which aggregates news from various sources including Reuters.

(RXST) Risk Channels and Responsive Allocation

This article from Stock Traders Daily analyzes Rxsight Inc. (NASDAQ: RXST), highlighting strong near- and mid-term sentiment but a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 98.0:1 risk-reward setup, targeting a 34.3% gain against 0.4% risk. The report provides …

Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis

Rxsight Inc (RXST) has a current financial score of 6.86, placing it 125 out of 199 in the Healthcare Equipment & Supplies industry. The company's financial status is stable with average operating efficiency, though its latest quarterly revenue decreased by 18.48% year-over-year and net …

RXST|Rxsight Inc|Price:5.865|Chg%:-0.185

RxSight, Inc. is a commercial-stage medical technology company that provides customized vision to cataract surgery patients through its proprietary RxSight Light Adjustable Lens system. The article details the company's profile, including its IPO date, CEO, number of employees, address, and key executives with their …

RxSight Number of Employees 2026 | Employee Count & Headcount Data

RxSight, Inc. (RXST) had approximately 469 employees worldwide as of March 2026, marking a 26.5% growth since 2023 but a 7.3% decline year-over-year in 2026. The company, headquartered in Aliso Viejo, California, is actively hiring with 18 job postings and its workforce is predominantly …

Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline

The market expects RxSight, Inc. (RXST) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

Rxsight Inc (RXST) Institutional Confidence

Rxsight Inc (RXST) has an institutional shareholding score of 10.00, placing it first in its industry. Institutional ownership stands at 93.24%, an 11.69% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.77% of outstanding shares.

RxSight (RXST) Projected to Announce Quarterly Earnings on Wednesday